TNF receptor II fusion protein with tandemly repeated Fc domains.

TNF receptor II fusion protein with tandemly repeated Fc domains.
复制标题

具有串联重复 Fc 结构域的 TNF 受体 II 融合蛋白。

DOI:
10.1093/jb/mvq149
复制
发表时间:
2011
影响因子:
2.7
通讯作者:
Y. Masuho
Y. Masuho
中科院分区:
生物学4区
文献类型:
--
作者:
H. Nagashima;Kaname Kaneko;Ayaka Yamanoi;Sotaro Motoi;S. Konakahara;J. Kohroki;Y. Masuho

文献摘要

参考文献

被引文献

相似文献

与人IgG 1 Fc区融合的肿瘤坏死因子(TNF)受体II的胞外结构域(TNFRII-Fc)以及抗TNF抗体已用于治疗类风湿性关节炎。然而,TNFRII-Fc在针对细胞表面上携带TNF的细胞的抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性(CDC)方面不如这些抗体有效。我们假设这些活性可以通过融合TNFRII与串联重复的Fc(TNFRII-Fc-Fc)来增加。TNFRII-Fc-Fc对可溶性TNF-α和跨膜TNF-α的亲和力和TNF-α细胞毒性抑制活性与TNFRII-Fc的亲和力和TNF-α细胞毒性抑制活性一样强。TNFRII-Fc-Fc对Fcγ受体的结合亲合力远高于TNFRII-Fc,并且在ADCC和CDC方面对表达跨膜TNF-α的细胞更有效。检测到80 kDa的TNFRII-Fc-Fc以及200 kDa的TNFRII-Fc-Fc。TNFRII-Fc-Fc(80 kDa)在ADCC和CDC方面与TNFRII-Fc一样有效。这些结果表明,受体-Fc融合蛋白的Fc多聚化可以增强效应子功能,如ADCC和CDC,从而具有提供上级治疗效果的潜力。不仅TNFRII-Fc如此,其他受体-Fc融合蛋白也是如此。
The extracellular domain of tumour necrosis factor (TNF) receptor II fused with the human IgG1 Fc region (TNFRII-Fc), as well as antibodies against TNF, has been used to treat rheumatoid arthritis. However, TNFRII-Fc is less effective than these antibodies in terms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against cells bearing TNF on the cell surface. We hypothesized that these activities could be increased by fusing TNFRII with tandemly repeated Fc (TNFRII-Fc-Fc). The affinities of TNFRII-Fc-Fc for soluble TNF-α and transmembrane TNF-α and the TNF-α cytotoxicity-inhibitory activity were as potent as those of TNFRII-Fc. TNFRII-Fc-Fc showed much higher binding avidity for Fcγ receptors than TNFRII-Fc and was more potent in terms of both ADCC and CDC against cells expressing transmembrane TNF-α. TNFRII-Fc-Fc of 80 kDa, as well as TNFRII-Fc-Fc of 200 kDa, was detected. TNFRII-Fc-Fc (80 kDa) was as potent as TNFRII-Fc in terms of both ADCC and CDC. These results suggest that Fc multimerization of receptor-Fc fusion proteins can augment effector functions such as ADCC and CDC, and thereby have the potential to provide a superior therapeutic effect. This may be the case not only for TNFRII-Fc but also for other receptor-Fc fusion proteins.
DOI: 10.1200/jco.2003.05.013
发表时间: 2003-11-01
影响因子: 45.3
作者:
Weng, WK;Levy, R
通讯作者: Levy, R
DOI: 10.1182/blood.v99.3.1038
发表时间: 2002-02-01
期刊: BLOOD
影响因子: 20.3
作者:
Byrd, JC;Kitada, S;Reed, JC
通讯作者: Reed, JC
DOI: 10.1182/blood-2006-04-020057
发表时间: 2006-10-15
期刊: BLOOD
影响因子: 20.3
作者:
Bowles, Julie A.;Wang, Siao-Yi;Weiner, George J.
通讯作者: Weiner, George J.
单体人 IgG 的结合定义了大颗粒淋巴细胞/自然杀伤细胞上 Fc gamma RIII 的表达多态性。
DOI: --
发表时间: 1993
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Vance,BA;Huizinga,TW;Wardwell,K;Guyre,PM
通讯作者: Guyre,PM